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Allopurinol for Heart Failure
Novel Mechanisms*
Lionel H. Opie, MD, DSC
Cape Town, South Africa
Oh, for oxygen is the cry that we could imagine coming
from the famished cardiomyocytes in heart failure (HF).
But how can energy in the form of adenosine triphosphate
(ATP) be conserved? The principles are much like those of
the economy: either cut the demand for dollars or increase
the supply or do both. A simple way of energy conservation
is to rest the heart, for example, by decreasing the heart rate
by beta-blockade or ivabridine. Equally simple is reduction
of the afterload by inhibition of the renin-angiotensin
system or by nitrate/hydralazine. “Is the failing heart
energy-starved,” asked Joanne Ingwall and Robert Weiss (1)
in 2004. In their view, yes, it is. “The failing heart—an
engine out of fuel” is how Stefan Neubauer (2) saw it. This
working hypothesis rests on many previous contributions
from Harvey onward, including those of Osler, Hill, Meer-
son, and many others, who have all contributed to the
varying concepts of HF, leading to the “modern” view as
outlined by Arnold Katz (3). Many of the current research
leaders have worked on basic biochemical aspects of models
of HF, but the present article focuses our attention on
chronic human HF and the proposal that allopurinol might
confer benefit.
See page 802
The accompanying paper in this issue of the Journal (4)
elps us to understand better the role of high-energy phos-
hate compounds in chronic human HF, a topic that goes back
o Hermann and Decherd (5) in 1939 who described a
ignificantly reduced creatine content in the failing heart.
efects in creatine led us right on to the fundamental advances
ade by the Johns Hopkins group, first defining the defects in
nergy metabolism in the human heart (6) and then providing
proposed therapeutic solution (4).
TP in the failing heart: increased synthesis. Already in
005, the Johns Hopkins group had studied the creatine
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Cape Town, South Africa.inase (CK) flux in human heart failure, finding that the
ux through CK was reduced by 50% in mild to moderate
F (6). Their critical technological advance was the use of
agnetic resonance imaging/magnetic resonance spectros-
opy to detect the energy flux of CK in the human heart.
he CK reaction is essential in 2 vital steps in energy
roduction. First, in the mitochondria, mitochondrial CK
onverts the ATP produced by oxidative phosphorylation to
hosphocreatine that then readily diffuses out of the mito-
hondria to become cytosolic phosphocreatine. Second,
ytosolic CK then promotes the resynthesis of cytosolic
TP from cytosolic adenosine diphosphate, thus being an
ssential link in the overall sequence of transfer of energy
rom the mitochondria to the contractile mechanism (see
ig. 1 in Neubauer [2]). The creatine required for these
eactions is not synthesized in the heart tissue, so that it
ust be taken up from the circulation by the creatine
ransporter (2).
An attractive hypothesis, strongly supported by the data
resented, is that the forward flux of energy through cytosolic
K is reduced in human HF. Thus, the heart lacks cytosolic
TP, the immediate source of energy for cardiac contraction.
he highly novel proposal of the current paper is that allopuri-
ol helps to reverse these unfavorable trends in high-energy
hosphate metabolism in those with chronic HF. Allopurinol
s much better known for its capacity to inhibit the xanthine
xidase reaction, thereby lessening the formation of uric acid
nd providing benefit in gout. As this site of action is far down
n the breakdown path of ATP, in fact as many as 5 reactions
way from ATP (Fig. 1), it is more than likely that only a
assive increase in hypoxanthine could help to preserve ATP
n the failing heart. Thus, an alternate site of action of
llopurinol should be considered.
By inhibiting xanthine oxidase, the proposal is that
llopurinol also inhibits the formation of reactive oxygen
pecies (ROS) (7,8). ROS, in turn, are inhibitors of the
ytosolic CK reaction. As ROS falls under the influence of
llopurinol, the CK reaction is enhanced and cytosolic ATP
s synthesized. In fact, the acceleration of the CK ratio in
he direction of ATP synthesis is exactly what their elegant
echnology could detect. Thus, the way is now paved for a
arger study on the proposed benefits of allopurinol in those
ith chronic HF (the EXACT-HF study). Due attention
ight be given to the possible nephrotoxicity of allopurinol,
reviously established (9) but recently argued against (10).
his possible safety issue might well warrant attention when
enal impairment accompanies HF.
ncreased ATP conservation. An entirely different ap-
roach to the energy problem in HF is not to enhance the
TP supply, but to make better use of the ATP that there
s. Metabolic measures that reduce the oxygen wastage
ound in advanced HF will indirectly improve the energy
upply. Here we need to revert to the consequences of excess
elivery to the myocardium of oxygen-inefficient free fatty
cids (FFAs) with subsequent preferential use of FFAs over
810 Opie JACC Vol. 59, No. 9, 2012
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fied concept of oxygen wastage is that glucose is “good” and
FFAs are “bad,” as can be explained by the differences in the
ATP yield per oxygen atom (P/O ratio), the values being
3.17 glucose versus 2.83 for palmitate, with approxi-
mately an 11% saving of oxygen when moving from one
extreme (only FFAs) to the other (only glucose). This
brings us to the time-honored but still controversial
concept of glucose-insulin-potassium, initially proposed
and only now being tested to counter the FFA increase in
early phase acute myocardial infarction in the ambulance.
Administering glucose-insulin-potassium as soon as pos-
sible after the onset of chest pain is important because
within 1 h in the baboon model there is already severe
depletion of high-energy phosphate compounds (13),
Figure 1 Proposed Sites of Action of Allopurinol in HF
Adenosine triphosphate (ATP) made in the mitochondria is converted to phosphocreat
able and is exported to the cytosol where it converts adenosine diphosphate (ADP) to
contractile mechanism to reform ADP, which is resynthesized by oxidative phosphoryla
breakdown paths below ADP are shown, eventually reaching the theoretically possible
cally reverse these reactions. The path from hypoxanthine to ATP requires as many as
nol in increasing cytosolic ATP. However, inhibition of xanthine oxidase by allopurinol b
right), which are increased in HF. The proposal is that such allopurinol-induced decrea
turn simulates the formation of cytosolic ATP from cytosolic PCr (top left), thereby pro
in blue. The 5 steps are: 1) hypoxanthine phosphoribosyl transferase; 2) inosine kina
tion. Also shown are: 6) adenine phosphoribosyl transferase; and 7) adenosine kinase
phate. Adapted from Opie LH. The Heart. Physiology and Metabolism. 2nd edition. Newhereas overall data in patients suggest that interventionswithin the first 1 to 2 “golden” hours of onset of pain are
most effective (14).
These concepts are relevant to HF. In optimally treated
HF patients, there was a 10% reduction in FFA oxidation
when inhibited by the drug trimetazidine, and the ejection
fraction increased, but myocardial efficiency was unchanged
(15). Although this finding supports the benefits of inhibi-
tion of myocardial FFA oxidation in HF, an intriguing
possibility is that the fatty acid–glucose interaction also
occurred in skeletal muscle as an additional site of action of
trimetazidine (16). Another metabolic modulator, perhexi-
line, has improved energy deficiency in patients with hyper-
trophic cardiomyopathy (17).
However, oxygen wastage with FFAs can be considerably
10%, especially when there is vigorous catecholamine
r) under the influence of mitochondrial creatine kinase. PCr is much more perme-
rough the activity of cytosolic creatine kinase (CKc). Cytosolic ATP is used by the
the mitochondria (mito). In states of ATP depletion such as heart failure (HF), the
own endpoint of uric acid. Allopurinol, by inhibiting xanthine oxidase, could theoreti-
thetic steps, making it a very unlikely mechanism to achieve the benefit of allopuri-
ith it decreased formation of cytosolic reactive oxygen species (ROS) (bottom
rmation of ROS in turn lessens the inhibition imposed by ROS on the CKc that in
energy for contraction in HF. Breakdown paths are shown in red and synthetic paths
vity; 3) low-activity salvage path; 4) myokinase activity; and 5) oxidative phosphoryla-
 adenosine monophosphate; FFA  free fatty acid; IMP  inosine monophos-
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h811JACC Vol. 59, No. 9, 2012 Opie
February 28, 2012:809–12 Allopurinol for Heart Failureexample, an infusion of isoproterenol increased the myocar-
dial oxygen consumption of the in situ dog heart by 91%, an
oxygen wastage that was halved by a glucose infusion or by
inhibitors of fatty acid oxidation (18).
Importantly, the glucose–fatty acid contrast extends be-
yond oxygen saving and wastage. Thus, glucose and fatty
acid metabolites also act on the paths of programmed cell
death, with the glucose metabolites inhibiting apoptosis,
especially in the presence of insulin and fatty acid metabo-
lites having the converse effects (19).
Does allopurinol both synthesize and conserve ATP? Per-
haps surprisingly, in pacing-induced HF in dogs, allopurinol
unexpectedly had 2 benefits, not only increasing myocardial
contractility but reducing cardiac energy requirements (20).
The mechanical efficiency (stroke work divided by oxygen
uptake) increased by 50% (Fig. 3 in Ekelund et al. [20]).
“The resultant boost in myocardial contractile efficiency may
prove beneficial in the treatment of congestive heart failure,”
concluded the authors, also appropriately from Johns Hop-
kins 20 years ago. The oxygen conservation and increase
efficiency of work in this study was not easily explained.
Two speculative possibilities were as follows. First, the
4-fold increase in xanthine oxidase activity in the dog study
(20) could have increased formation of ROS (measured as
superoxide), and, second, there was an enhanced response of
the myofilaments to calcium. Thus, allopurinol may be both
producing and conserving more ATP. The latter could be
explained as follows. Inhibition of CK in rat hearts lowers
free-energy release, which, in turn, limits the Ca2-
andling capacity of the sarcoplasmic reticular Ca2ATPase
(21). Thus, allopurinol, by promoting the activity of cyto-
solic CK (6), would have the opposite effect. Allopurinol
also increased myocardial efficiency in patients with idio-
pathic dilated cardiomyopathy (22), so that the findings of
these animal studies are applicable to humans.
Is the dose relevant? In extrapolating from acute to
chronic studies, the single intravenous dose of allopurinol
200 mg given to a 25-kg dog corresponds to 600 mg given
to a 75-kg person. In the present paper, 300 mg was given
acutely by intravenous injection, which would create a
higher peak allopurinol blood level when compared with a
standard human oral dose that goes up to 300 mg with
probably much lower peak levels. Nevertheless, in chronic
HF trials with oral allopurinol and when there is accompa-
nying renal failure, there might be accumulation of allopuri-
nol and its active metabolites with a risk of renotoxicity.
Study limitations. These are few. The present study lacks
strict controls, and the placebo group was small. However,
the crux was the metabolic effects of allopurinol in the same
patients, and there were no metabolic changes in the
placebo group. Thus, the study, although limited in statis-
tical power, provides sufficient hard mechanistic data to
justify future larger therapeutic studies. Second, basic work
suggests that there are 2 pathways of energy transfer from
mitochondria to the cytosol. In addition to energy transfer
through the CK shuttle, as studied here, there could bedirect ATP transfer from mitochondria to cytosol (23).
However, the latter proposal needs confirmation and
quantification.
For the further future? Finally, an invigorating aspect of
the proposed further testing of allopurinol in human HF is
that the drug is freely available and inexpensive, besides
having a novel mode of action. To gain maximal metabolic
benefit, both producing ATP and maximally conserving
ATP should be considered. Thus, allopurinol could now be
tested with glucose-insulin vigorously to oppose myocardial
oxygen wastage and to increase the myocardial ATP even
more, thereby co-coordinating 2 different metabolic mech-
anisms to save the myocardium threatened by energy deple-
tion in chronic HF.
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